Immuron Aims to Secure FDA Approval for IMM-124E to Prevent Travelers’ Diarrhea
April 11, 2019 09:00 ET
|
Immuron Limited
Key Points Immuron to develop U.S. registration dossier for IMM-124E for Travelers’ DiarrheaCompany anticipates significant inflection in sales with successful FDA registration of IMM-124ECompany to...
Immuron Reports Significant Alleviation of Colitis Symptoms in Preclinical Program
May 07, 2018 21:43 ET
|
Immuron Limited
MELBOURNE, Australia, May 07, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally...
Immuron to Receive $2.16M R&D Tax Concession Refund
January 24, 2018 09:30 ET
|
Immuron Limited
Melbourne, Australia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) is pleased to announce that under the Australian Government’s Research and Development...
Immuron Granted US Patent for NASH Treatment
November 15, 2017 09:00 ET
|
Immuron Limited
MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercialising oral...
Immuron Successfully Completes NASH Phase II Clinical Study Milestone
November 09, 2017 09:00 ET
|
Immuron Limited
MELBOURNE, Australia, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercialising oral...